摘要
目的了解胆道与腹腔分离大肠埃希菌产超广谱β-内酰胺酶(ESBLs)菌株的发生率及其耐药性。方法CLSI表型确证试验(纸片增强法)检测产ESBLs菌株,琼脂稀释法进行药敏试验。结果47株胆道与腹腔分离大肠埃希菌中,产ESBLs菌株的发生率为50.1%;产ESBLs菌株对氨苄西林、第一、二代头孢菌素、氟喹诺酮类、头孢噻肟耐药显著,对头孢他啶、头孢吡肟、头孢哌酮/舒巴坦、阿米卡星、头孢美唑耐药率<40.0%,对美罗培南的耐药率为0;非产ESBLs菌株对氨苄西林、第一、二代头孢菌素、氟喹诺酮类耐药率较高,对其他抗菌药物均较为敏感;产ESBLs菌株对第一、二代头孢菌素、环丙沙星、头孢噻肟耐药率显著高于非产ESBLs菌株差异有统计学意义(P<0.05)。结论胆道与腹腔分离大肠埃希菌中产ESBLs菌株的发生率较高,产ESBLs菌株多药耐药显著,临床应加强检测和监测。
OBJECTIVE To investigate the prevalence of extended-spectrum β-lactamases (ESBLs) and the resistance in Escherichia coli isolates from biliary tract and abdominal cavity. METHODS ESBLs-producers were detected by CLSI Phenotypic Confirmatory Test and susceptibilities were tested by agar dilution method. RESULTS 50.1% Of isolates were ESBLs producers in those isolates. ESBLs producers were highly resistant to ampicillin, cefazolin, cefuroxime, fluoroquinolones, and cefotaxime. The resistant rate to ceftazidime, cefepime, cefoperazone-sulbactam, amikacin, and cefmetazole was less than 40%. None was resistant to meropenem in ESBLs producers. In non-ESBLs producers the resistant rate to ampicillin, cefazolin, cefuroxime, fluoroquinolones was more than 40% and most were susceptible to other antimicrobial agents. The resistant rate to ampicillin, cefazolin, cefuroxime, and ciprofloxacin was significantly higher in ESBLs producers than non- ESBLs producers. CONCLUSIONS With resistance to most of antimicrobial agents, ESBLs-producers were highly prevalent in E. coli isolates from biliary tract and abdominal cavity, so more attention should be paid to survey and detect those strains.
出处
《中华医院感染学杂志》
CAS
CSCD
北大核心
2009年第5期583-585,共3页
Chinese Journal of Nosocomiology